Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women’s health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
American Cancer Society. Cancer facts & figures 2019. Atlanta: American Cancer Society https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html (2019).
Amant, F., Mirza, M. R., Koskas, M. & Creutzberg, C. L. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 143 Suppl 2, 37–50 (2018).
Gruber, S. B. & Thompson, W. D. A population-based study of endometrial cancer and familial risk in younger women. Cancer and steroid hormone study group. Cancer Epidemiol. Biomarkers Prev. 5, 411–417 (1996).
Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D. & Hitchins, M. P. Milestones of lynch syndrome: 1895–2015. Nat. Rev. Cancer 15, 181–194 (2015).
Palles, C., Latchford, A. & Valle, L. in Hereditary Colorectal Cancer (eds Valle, L., Gruber, S. & Capellá, G.) 113–134 (Springer, 2018).
Ngeow, J., Stanuch, K., Mester, J. L., Barnholtz-Sloan, J. S. & Eng, C. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J. Clin. Oncol. 32, 1818–1824 (2014).
Gaber, C., Meza, R., Ruterbusch, J. J. & Cote, M. L. Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040. J Racial Ethn. Health Disparities 4, 895–903 (2017).
Setiawan, V. W. et al. Type I and II endometrial cancers: have they different risk factors? J. Clin. Oncol. 31, 2607–2618 (2013).
Brinton, L. A. et al. Etiologic heterogeneity in endometrial cancer: evidence from a gynecologic oncology group trial. Gynecol. Oncol. 129, 277–284 (2013).
Lortet-Tieulent, J., Ferlay, J., Bray, F. & Jemal, A. International patterns and trends in endometrial cancer incidence, 1978-2013. J. Natl. Cancer Inst. 110, 354–361 (2018).
Clarke, M. A., Devesa, S. S., Harvey, S. V. & Wentzensen, N. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J. Clin. Oncol. https://doi.org/10.1200/JCO.19.00151 (2019).
Faber, M. T., Frederiksen, K., Jensen, A., Aarslev, P. B. & Kjaer, S. K. Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978-2014. Gynecol. Oncol. 146, 359–367 (2017).
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B. & Reis-Filho, J. S. Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. 8, 261–271 (2011).
Noone A. M. et al. SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/ (2018).
Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013). Landmark TCGA study that reports the molecular genomic landscape of endometrioid and serous endometrial carcinomas, defining four distinct molecular subgroups.
Cherniack, A. D. et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 31, 411–423 (2017). Landmark TCGA study that reports the molecular genomic landscape of 57 uterine carcinosarcomas.
Le Gallo, M. et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat. Genet. 44, 1310–1315 (2012).
Le Gallo, M. et al. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124, 65–73 (2018).
Le Gallo, M. et al. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer 123, 3261–3268 (2017).
Jones, S. et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat. Commun. 5, 5006 (2014).
DeLair, D. F. et al. The genetic landscape of endometrial clear cell carcinomas. J. Pathol. 243, 230–224 (2017).
Kinde, I. et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 5, 167ra164 (2013). First study to show that endometrial cancer-associated mutations can be detected during routine Pap tests; led to development of the prototype ‘PapGene’ test (2013).
Zhao, S. & Santin, A. D. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proc. Natl. Acad. Sci. USA 113, 12238–12243 (2016).
Kuhn, E. et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J. Natl. Cancer Inst. 104, 1503–1513 (2012).
McConechy, M. K. et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 228, 20–30 (2012).
Felix, A. S. et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 21, 1851–1856 (2010).
Sherman, M. E. et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod. Pathol. 10, 963–968 (1997).
Yang, H. P. et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP diet and health study. Am. J. Epidemiol. 177, 142–151 (2013).
Mutter, G. L., Monte, N. M., Neuberg, D., Ferenczy, A. & Eng, C. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res. 74, 2796–2802 (2014).
Levine, R. L. et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 58, 3254–3258 (1998).
Mutter, G. L. et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 92, 924–930 (2000).
Lin, M. C., Burkholder, K. A., Viswanathan, A. N., Neuberg, D. & Mutter, G. L. Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer 115, 2111–2118 (2009).
Russo, M. et al. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. Hum. Pathol. 67, 69–77 (2017).
Lazo de la Vega, L. et al. Multiclonality and marked branched evolution of low-grade endometrioid endometrial carcinoma. Mol. Cancer Res. 17, 731–740 (2019).
Mota, A. et al. Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. Mod. Pathol. 30, 134–145 (2017).
Joshi, A., Miller, C. Jr., Baker, S. J. & Ellenson, L. H. Activated mutant p110alpha causes endometrial carcinoma in the setting of biallelic Pten deletion. Am. J. Pathol. 185, 1104–1113 (2015).
Urick, M. E. et al. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 71, 4061–4067 (2011).
Cheung, L. W. et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1, 170–185 (2011).
Oda, K. et al. PIK3CA cooperates with other phosphatidylinositol 3’-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 68, 8127–8136 (2008).
Oda, K., Stokoe, D., Taketani, Y. & McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669–10673 (2005).
Terakawa, J. et al. Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities. Proc. Natl. Acad. Sci. USA 116, 4528–4537 (2019).
Wang, H. et al. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am. J. Pathol. 160, 1481–1486 (2002).
Byron, S. A. et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLOS ONE 7, e30801 (2012).
Wang, X., Khatri, S., Broaddus, R., Wang, Z. & Hawkins, S. M. Deletion of Arid1a in reproductive tract mesenchymal cells reduces fertility in female mice. Biol. Reprod. 94, 93 (2016).
Kim, T. H. et al. ARID1A Is essential for endometrial function during early pregnancy. PLOS Genet. 11, e1005537 (2015).
Ayhan, A. et al. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. J. Pathol. Clin. Res. 1, 186–193 (2015).
Sherman, M. E., Bur, M. E. & Kurman, R. J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 26, 1268–1274 (1995).
Lax, S. F., Kendall, B., Tashiro, H., Slebos, R. J. & Hedrick, L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88, 814–824 (2000).
Wild, P. J. et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol. Med. 4, 808–82 (2012).
Daikoku, T. et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 68, 5619–5627 (2008).
Kuhn, E., Bahadirli-Talbott, A. & Shih Ie, M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod. Pathol. 27, 1014–1019 (2014).
Zhao, S. et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl. Acad. Sci. USA 110, 2916–2912 (2013).
Rudd, M. L. et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin. Cancer Res. 17, 1331–1340 (2011).
Haesen, D. et al. Recurrent PPP2R1A mutations in uterine cancer act through a dominant-negative mechanism to promote malignant cell growth. Cancer Res. 76, 5719–5731 (2016).
Urick, M. E. & Bell, D. W. In vitro effects of FBXW7 mutation in serous endometrial cancer: increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib. Mol. Carcinog. 57, 1445–1457 (2018).
McConechy, M. K. et al. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. J. Pathol. Clin. Res. 1, 173–185 (2015).
Chiyoda, T. et al. Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma? Genes Chromosomes Cancer 51, 229–239 (2012).
Jin, Z. et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int. J. Gynecol. Pathol. 22, 368–373 (2003).
Abeln, E. C. et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J. Pathol. 183, 424–431 (1997).
Wada, H. et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 57, 5379–5385 (1997).
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016).
Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
An, H. J., Logani, S., Isacson, C. & Ellenson, L. H. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol. 17, 530–537 (2004).
Hoang, L. N. et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology 66, 664–674 (2014).
Han, G. et al. Endometrial carcinomas with clear cells: a study of a heterogeneous group of tumors including interobserver variability, mutation analysis, and immunohistochemistry with HNF-1beta. Int. J. Gynecol. Pathol. 34, 323–333 (2015).
Stelloo, E. et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod. Pathol. 28, 836–844 (2015).
McConechy, M. K. et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin. Cancer Res. 22, 2865–2873 (2016).
Church, D. N. et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl. Cancer Inst. 107, 402 (2015).
Meng, B. et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 134, 15–19 (2014).
Hussein, Y. R. et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod. Pathol. 28, 505–514 (2015).
Billingsley, C. C. et al. Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121, 386–394 (2015).
van Gool, I. C. et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin. Cancer Res. 21, 3347–33557 (2015).
Bellone, S. et al. Polymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4+T cell responses in endometrial cancer patients. Gynecol. Oncol. 138, 11–17 (2015).
Shukla, S. A., Howitt, B. E., Wu, C. J. & Konstantinopoulos, P. A. Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecol. Oncol. Rep. 19, 42–45 (2017).
Howitt, B. E. et al. Association of Polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1, 1319–1323 (2015).
Eggink, F. A. et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 6, e1264565 (2017).
Bellone, S. et al. Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol. Oncol. 144, 146–152 (2017).
Van Gool, I. C. et al. Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues. Clin. Cancer Res. 24, 3197–3203 (2018).
Talhouk, A. et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin. Cancer Res. 25, 2537–2548 (2019).
Clarke, M. A. et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern. Med. 178, 1210–1222 (2018).
Wang, Y. et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci. Transl. Med. 10, eaap8793 (2018). Publication demonstrating the detection of early-stage endometrial cancers from samples collected during routine Pap tests using the ‘PapSEEK’ test (2018).
Del Priore, G. et al. Endometrial brush biopsy for the diagnosis of endometrial cancer. J. Reprod. Med. 46, 439–443 (2001).
Kipp, B. R. et al. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study. Cancer 114, 228–235 (2008).
Maksem, J., Sager, F. & Bender, R. Endometrial collection and interpretation using the Tao brush and the CytoRich fixative system: a feasibility study. Diagn. Cytopathol. 17, 339–346 (1997).
Wu, H. H., Casto, B. D. & Elsheikh, T. M. Endometrial brush biopsy. An accurate outpatient method of detecting endometrial malignancy. J. Reprod. Med. 48, 41–45 (2003).
Nair, N. et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study. PLOS Med. 13, e1002206 (2016).
Maritschnegg, E. et al. Lavage of the uterine cavity for molecular detection of mullerian duct carcinomas: a proof-of-concept study. J. Clin. Oncol. 33, 4293–4300 (2015).
Suda, K. et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 24, 1777–1789 (2018).
Anglesio, M. S. et al. Cancer-associated mutations in endometriosis without cancer. N. Engl. J. Med. 376, 1835–1848 (2017).
Guo, S. W. Cancer driver mutations in endometriosis: variations on the major theme of fibrogenesis. Reprod. Med. Bio.l 17, 369–397 (2018).
Martignetti, J. A. et al. Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. Cold Spring Harb. Mol. Case Stud. 4, pii: a003269 (2018).
Bakkum-Gamez, J. N. et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol. Oncol. 137, 14–22 (2015).
Fiegl, H. et al. Methylated DNA collected by tampons — a new tool to detect endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 13, 882–888 (2004).
Talhouk, A. et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 113, 299–310 (2015).
Wortman, B. G. et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br. J. Cancer 119, 1067–1074 (2018).
Stelloo, E. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 22, 4215–4224 (2016). Description of the Trans PORTEC molecular classification system that is currently being tested in clinical trials of endometrial cancer patients.
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03469674 (2018).
Auguste, A. et al. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Mod. Pathol. 31, 1851–1861 (2018).
Talhouk, A. et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123, 802–813 (2017).
Kommoss, S. et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann. Oncol. 29, 1180–1188 (2018). Description of the ‘locked down’ ProMisE molecular classifier that is now ready for clinical evaluation (2018).
Britton, H. et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol. Oncol. 153, 487–495 (2019).
Stelloo, E. et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol. Oncol. 133, 197–204 (2014).
Talhouk, A. & McAlpine, J. N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol. Oncol. Res. Pract. 3, 14 (2016).
Kurnit, K. C. et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod. Pathol. 30, 1032–1041 (2017).
Myers, A., Barry, W. T., Hirsch, M. S., Matulonis, U. & Lee, L. Beta-catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol. Oncol. 134, 426–427 (2014).
Wortman, B. G. et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecol. Oncol. 151, 69–75 (2018).
Soslow, R. A. et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int. J. Gynecol. Pathol. 38 Suppl 1, S64–S74 (2019).
Meric-Bernstam, F. et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J. Clin. Oncol. 33, 2753–2762 (2015).
Stockley, T. L. et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 8, 109 (2016).
Wheler, J. J. et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 76, 3690–3701 (2016).
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Soumerai, T. E. et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin. Cancer Res. 24, 5939–5947 (2018).
Chawla, A. et al. Estimated cost of anticancer therapy directed by comprehensive genomic profiling in a single-center study. JCO Precis. Oncol. 2, 1–11 (2018).
Meng, X. et al. AZD1775 Increases sensitivity to olaparib and gemcitabine in cancer cells with p53 mutations. Cancers (Basel) 10, E149 (2018).
Meng, X. et al. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet. Gynecol. Int. 2013, 828165 (2013).
Ebeid, K. et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat. Nanotechnol. 13, 72–81 (2018).
Meng, X. et al. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecol. Oncol. 128, 461–469 (2013).
Freedman, A. N. et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. JCO Precis. Oncol. 2, 1–13 (2018).
Rodon, J. et al. WINTHER: an international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. J. Clin. Oncol. 36, 12011 (2018).
Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov. 7, 586–595 (2017).
Schwaederle, M. et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2, 1452–1459 (2016).
Jardim, D. L. et al. Impact of a biomarker-based strategy on oncology drug development: A meta-analysis of clinical trials leading to FDA approval. J. Natl. Cancer Inst. 107 pii: djv253 (2015).
Tsimberidou, A. M. et al. Personalized medicine in a phase I clinical trials program: the MD Anderson cancer center initiative. Clin. Cancer Res. 18, 6373–6383 (2012).
Lheureux, S. & Oza, A. M. Endometrial cancer-targeted therapies myth or reality? review of current targeted treatments. Eur. J. Cancer 59, 99–108 (2016).
Dedes, K. J. et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2, 53ra75 (2010).
Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).
Miyasaka, A. et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer 14, 179 (2014).
Bian, X. et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37, 341–351 (2018).
Dosil, M. A. et al. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias. J. Pathol. 242, 152–164 (2017).
Fader, A. N. et al. Randomized phase ii trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin. Oncol. 36, 2044–20516 (2018).
Musselman, K. et al. Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. Gynecol. Oncol. Rep. 28, 54–57 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01775072 (2019).
Bergstrom, C. P., Geest, K., O’Gara, R., Corless, C. L. & Morgan, T. K. Discordant mutations in paired primary and metastatic endometrial adenocarcinomas identified by semiconductor-based sequencing for rapid cancer genotyping. Reprod. Sci. 23, 1575–1579 (2016).
Gibson, W. J. et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848–55 (2016).
Ashley, C. W. et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol. Oncol. 152, 11–19 (2019).
Soslow, R. A. et al. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Am. J. Surg. Pathol. 36, 1771–1781 (2012).
Ta, R. M., Hecht, J. L. & Lin, D. I. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Gynecol. Oncol. 151, 401–406 (2018).
Reiter, J. G. et al. Minimal functional driver gene heterogeneity among untreated metastases. Science 361, 1033–1037 (2018).
Barroilhet, L. & Matulonis, U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecol. Oncol. 148, 585–590 (2018).
Mangat, P. K. et al. Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00122 (2018).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ (2019).
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017). Study describing the efficacy of single-agent pembrolizumab in mismatch repair-deficient endometrial cancer patients.
Cosgrove, C. M. et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol. Oncol. 146, 588–595 (2017).
McMeekin, D. S. et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study. J Clin. Oncol. 34, 3062–3068 (2016).
Zighelboim, I. et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin. Oncol. 25, 2042–2048 (2007).
Ott, P. A. et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study. J Clin. Oncol. 35, 2535–2541 (2017).
Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S. & Amant, F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol. Immunother. 63, 545–557 (2014).
Mitchell, T. C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.78.9602 (2018).
Mehnert, J. M. et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J. Clin. Invest. 126, 2334–4 (2016).
Fleming, G. F. et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). J. Clin. Oncol. 35, 15_suppl, 5585–5585 (2017).
Berger, A. C. et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33, 690–705 (2018).
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 e814 (2018).
Chan, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551–556 (2019).
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511–516 (2019).
Kategaya, L., Perumal, S. K., Hager, J. H. & Belmont, L. D. Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability. iScience 13, 488–497 (2019).
Lieb, S. et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife 8, e43333 (2019).
McConechy, M. K. et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod. Pathol. 27, 128–1347 (2014).
Jeske, Y. W. et al. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 145, 366–373 (2017).
Tashiro, H. et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150, 177–185 (1997).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01876511 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02178722 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02054806 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01375842 (2018).
Wong, A. & Ngeow, J. Hereditary syndromes manifesting as endometrial carcinoma: how can pathological features aid risk assessment? Biomed. Res. Int. 2015, 219012 (2015).
The authors apologize to those authors whose work we could not cite owing to space limitations. This work was supported by the Intramural Research Program of the National Human Genome Research Institute at NIH (HG200338 and HG200379) to D.W.B.
D.W.B. receives royalty income from US patent no. 7,294,468 ‘Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments’, which is licensed to Esoterix Genetic Labs LLC. M.E.U. has no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Tumour comprising both carcinoma and sarcoma.
Surgical removal of the uterus.
- Epithelial-to-mesenchymal transition
(EMT). Process by which epithelial cells acquire characteristics of mesenchymal cells, including but not limited to decreased cell-to-cell adhesion, decreased polarity and increased motility.
Cancer caused by uncontrolled proliferation of epithelial cells.
- Complex atypical hyperplasia
(CAH). When occurring in the endometrium, precancerous changes in the epithelial cells lining the uterus, characterized by abnormal growth and the acquisition of somatic genomic aberrations.
- Ovarian insufficiency
Loss of normal ovarian function.
- Mismatch repair
(MMR). Type of DNA repair that corrects base–base mismatches and insertions/deletions.
- Atrophic endometrium
Thin layer of nonproliferative epithelial cells lining the uterus; characteristic of postmenopausal women.
- Serous endometrial intraepithelial carcinoma
(SEIC). Noninvasive malignant precursor to serous endometrial cancer.
Cancer caused by uncontrolled proliferation of connective tissue.
- The Cancer Genome Atlas
(TCGA). NIH-funded initiative that molecularly characterized over 20,000 primary cancer and matched normal samples, covering 33 cancer types.
- Progression-free survival
(PFS). Length of time a patient lives without objective worsening of disease.
- Microsatellite instability
(MSI). Alteration of the number of short, repeated sequences of DNA because of a defect in DNA mismatch repair.
- Disease-free survival
Length of time a patient lives without signs of disease.
- Papanicolaou (Pap) test
Routine screening tool in which cervical cells are collected using a small brush and are analysed microscopically for signs of disease (e.g., irregular cell morphology).
- Tao brush
Flexible brush used to sample the inside of the uterus.
- Pap brush
Flexible brush used to sample the inside of the cervix.
- Next-generation sequencing
(NGS). High-throughput technologies (also known as massively parallel or deep sequencing) that enable faster determination of DNA or RNA base pair codes than previously used technologies (e.g. Sanger sequencing) were capable of.
- Uterine lavage
Process by which the uterus is flushed with a sterile solution.
Colorectal cancer screening test that enables patients to collect stool samples in-home; samples are mailed to a lab where they are analysed for the presence of blood and DNA abnormalities.
- Lymphovascular space invasion
(LVSI). Spreading of cancer to the lymphatic system or blood vessels.
Chemotherapy drug that inhibits cell growth and/or causes apoptosis by inducing DNA–DNA and DNA–protein crosslinks.
Chemotherapy drug that binds tubulin and inhibits cell division; also induces apoptosis through binding and inhibition of B cell leukaemia 2.
Recombinant monoclonal humanized epidermal growth factor receptor 2 antibody.
- Tumour-infiltrating lymphocytes
(TILs). White blood cells (immune cells) found within tumour tissue.
- TCGA’s Pan-Gyn cohort
The 1,087 invasive breast carcinomas, 308 endocervical adenocarcinomas, 579 high-grade serous ovarian cystadenocarcinomas, 548 uterine corpus endometrial carcinomas and 57 uterine carcinosarcomas molecularly characterized by TCGA.
About this article
Cite this article
Urick, M.E., Bell, D.W. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 19, 510–521 (2019). https://doi.org/10.1038/s41568-019-0177-x
Cell Death Discovery (2021)
Molecular Cancer (2020)
BMC Cancer (2020)
Cancer Cell International (2020)
Journal of Proteins and Proteomics (2020)